Trial Outcomes & Findings for Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas (NCT NCT04376567)

NCT ID: NCT04376567

Last Updated: 2025-09-11

Results Overview

Functional clinical patency means the number of participants who were able to use their brachial basilic arteriovenous fistula (BBAVF) successfully for dialysis within 6 months of surgical creation. It refers to using two dialysis needles in at least 75% of dialysis sessions over four weeks without need for additional procedure or surgery, as determined by their providers.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

2 participants

Primary outcome timeframe

6 months

Results posted on

2025-09-11

Participant Flow

Participant milestones

Participant milestones
Measure
One Stage Approach
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Two Stage Approach
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Overall Study
STARTED
1
1
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
1
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
One Stage Approach
n=1 Participants
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Two Stage Approach
n=1 Participants
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Total
n=2 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
1 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Sex: Female, Male
Female
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Sex: Female, Male
Male
1 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
1 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Dialysis
1 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 6 months

Functional clinical patency means the number of participants who were able to use their brachial basilic arteriovenous fistula (BBAVF) successfully for dialysis within 6 months of surgical creation. It refers to using two dialysis needles in at least 75% of dialysis sessions over four weeks without need for additional procedure or surgery, as determined by their providers.

Outcome measures

Outcome measures
Measure
One Stage Approach
n=1 Participants
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Two Stage Approach
n=1 Participants
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Number of Participants Who Had Successful Use of Arteriovenous Fistula for Dialysis
1 Participants
1 Participants

SECONDARY outcome

Timeframe: 6 months

Number of participants with dialysis catheter related complications, including infection, procedure to exchange catheter due to malfunction. outcomes of Primary Clinical Functional Patency or CVC-related bacteremia or death

Outcome measures

Outcome measures
Measure
One Stage Approach
n=1 Participants
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Two Stage Approach
n=1 Participants
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Number of Participants Who Had Catheter Related Complications
1 Participants
1 Participants

SECONDARY outcome

Timeframe: 6 months

Number of participants who had \> 3 months of catheter dependency after arteriovenous fistula creation

Outcome measures

Outcome measures
Measure
One Stage Approach
n=1 Participants
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Two Stage Approach
n=1 Participants
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Number of Participants Who Had > 3 Months of Catheter Dependency After Arteriovenous Creation
0 Participants
0 Participants

SECONDARY outcome

Timeframe: 6-month

Population: Participate did not complete PROMIS questionnaire.

Average quality of life scores assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) for physical function, fatigue, sleep disturbance, and ability to participate in social roles and activities. Data are presented as T-score, which are standardized scores with a mean of 50 and a standard deviation for the reference population (typically the US general population). A T-score of 50 represents the population average. A higher T-score indicates more of the concept being measured and lower T-score indicate less.

Outcome measures

Outcome measures
Measure
One Stage Approach
n=1 Participants
To create a brachial-basilic arteriovenous fistula (BBAVF) using a one-stage approach. The arteriovenous anastomosis is performed and the basilic vein is transposed during the same procedure. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Two Stage Approach
To create a BBAVF using a two-stage approach, the arteriovenous anastomosis is performed during the first procedure. The superficialization or transposition of the fistula is then performed 6 to 8 weeks later, after the fistula has matured. One stage approach: Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
Patient-Reported Outcomes Measurement Information System Scores Over 6 Months
Physical function (T-score)
37.5 score on a scale
Standard Deviation 33.2
Patient-Reported Outcomes Measurement Information System Scores Over 6 Months
Fatigue (T-score)
52.3 score on a scale
Standard Deviation 61.6
Patient-Reported Outcomes Measurement Information System Scores Over 6 Months
Sleep disturbance (T-score)
53.6 score on a scale
Standard Deviation 39.6
Patient-Reported Outcomes Measurement Information System Scores Over 6 Months
Ability to participate in social roles and activities (T-score)
44.7 score on a scale
Standard Deviation 23.7

Adverse Events

One Stage Approach

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Two Stage Approach

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Tze-Woei Tan

University of Arizona

Phone: 3234426835

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place